Zydus Lifesciences Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Zydus Lifesciences Limited Pharmaceutical Export Portfolio Dataset — 81 Products, $346.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zydus Lifesciences Limited — Pharmaceutical Exporter Profile (2026) | 81 Products, $346.3M Trade | TransData Nexus

Zydus Lifesciences Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $346.3M Total Trade · DGFT Verified

Zydus Lifesciences Limited is an Indian pharmaceutical exporter with a total trade value of $346.3M across 81 products in 25 therapeutic categories. Based on 9,173 verified export shipments from Indian Customs (DGFT) records, Zydus Lifesciences Limited is the #1 Indian exporter in 11 products including Losartan, Carvedilol, Iron. Top exports include Losartan ($28.1M), Carvedilol ($21.9M), Iron ($21.6M).

Zydus Lifesciences Limited — Export Portfolio & Destination Treemap

Zydus Lifesciences Limited pharmaceutical export portfolio — 81 products across 25 therapeutic categories. Source: Indian Customs (DGFT).

Who is Zydus Lifesciences Limited? — Company Overview & Market Position

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is a leading Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. Established in 1952 by the late Mr. Ramanbhai B. Patel, the company has evolved into a fully integrated global healthcare provider. As of March 2025, Zydus Lifesciences reported a turnover exceeding ₹23,200 crores, reflecting significant financial growth from ₹250 crores in 1995.

The company operates under the Corporate Identification Number (CIN) L24230GJ1995PLC025878. It employs over 27,917 individuals worldwide, including more than 1,400 scientists dedicated to research and development. Zydus Lifesciences is a publicly listed entity on the National Stock Exchange of India (NSE) under the ticker symbol ZYDUSLIFE and on the Bombay Stock Exchange (BSE) with the code 532321. The company's official website is www.zyduslife.com.

What Does Zydus Lifesciences Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Losartan$28.1M 2

Product Portfolio — Top 30 by Export Value

Zydus Lifesciences Limited exports 81 pharmaceutical products across 25 therapeutic categories. Market leader (#1 exporter) in 11 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Losartan	Cardiovascular	$28.1M	562	9.3%	1
2	Carvedilol	Cardiovascular	$21.9M	656	22.3%	1
3	Iron	Vitamins & Supplements	$21.6M	432	4.4%	1
4	Mesalamine	Gastrointestinal	$19.3M	386	1.5%	1
5	Omeprazole	Gastrointestinal	$13.2M	313	2.1%	8
6	Potassium	Nutritional Supplements	$13.1M	262	2.0%	3
7	Spironolactone	Diuretics	$13.1M	262	6.6%	1
8	Chloroquine	Antimalarial & Antiparasitic	$13.0M	260	7.6%	1
9	Hydroxychloroquine	Antimalarial & Antiparasitic	$12.9M	259	9.2%	1
10	Calcium	Vitamins & Supplements	$11.7M	233	1.3%	9
11	Fluconazole	Antifungals	$11.1M	221	12.0%	1
12	Metformin	Diabetes & Endocrine	$9.8M	196	2.1%	9
13	Apixaban	Cardiovascular	$8.1M	194	4.5%	5
14	Gabapentin	CNS & Psychiatric	$7.3M	145	0.8%	7
15	Nystatin	Antifungals	$6.4M	207	12.2%	2
16	Meloxicam	Analgesics & Antipyretics	$6.2M	184	3.1%	3
17	Azithromycin	Antibiotics	$6.0M	161	3.3%	7
18	Amlodipine	Cardiovascular	$5.6M	263	0.0%	13
19	Tramadol	Analgesics & Antipyretics	$5.5M	208	1.4%	9
20	Azathioprine	Immunosuppressants	$5.1M	102	15.1%	2
21	Vaccine	Other	$4.5M	90	0.4%	12
22	Acyclovir	Antivirals	$4.3M	128	3.4%	4
23	Methylprednisolone	Corticosteroids	$4.0M	127	13.7%	2
24	Prednisolone	Respiratory	$4.0M	127	4.2%	7
25	Doxycycline	Antibiotics	$3.9M	78	3.3%	1
26	Atenolol	Cardiovascular	$3.8M	200	9.4%	4
27	Leflunomide	Immunosuppressants	$3.8M	75	25.2%	1
28	Oseltamivir	Antivirals	$3.8M	75	3.1%	6
29	Anastrozole	Advanced Oncology	$3.6M	111	3.2%	2
30	Celecoxib	Analgesics & Antipyretics	$3.6M	149	2.7%	7

Zydus Lifesciences Limited exports 81 pharmaceutical products across 25 therapeutic categories with a total export value of $346.3M. The company is the #1 Indian exporter in 11 products: Losartan, Carvedilol, Iron, Mesalamine, Spironolactone and 5 more. The top category is Cardiovascular (23.2% of portfolio), followed by Gastrointestinal (10.9%), reflecting a diversified portfolio where the top 5 products account for only 30.0% of total value.

Showing top 30 of 81 products. Contact us for complete data.

Zydus Lifesciences Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Zydus Lifesciences operates a robust network of manufacturing facilities across India, including states such as Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. Globally, the company has manufacturing sites in the United States, Brazil, Myanmar, and the United Kingdom. These facilities are equipped to produce a diverse range of pharmaceutical products, including finished dosage forms, active pharmaceutical ingredients (APIs), vaccines, biosimilars, and complex products.

3Key Leadership

The leadership team at Zydus Lifesciences is headed by Mr. Pankaj R. Patel, who serves as the Chairman. Dr. Sharvil P. Patel holds the position of Managing Director and Executive Director. Other key executives include Mr. Tushar Dhansukh Shroff, President of Finance and Chief Financial Officer, and Mr. Dhaval Narendra Soni, Company Secretary and Compliance Officer.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Zydus Lifesciences Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Zydus Lifesciences has a significant presence in regulated markets, including the United States, Europe (France and Spain), the United Kingdom, Australia, and Japan. The company has established manufacturing facilities and research centers in these regions, enabling it to meet the stringent regulatory standards required for market access. Zydus Lifesciences has received approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for various pharmaceutical products. The company's commitment to quality and compliance has facilitated its entry and sustained presence in these markets.

2Emerging Markets

Zydus Lifesciences has strategically expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in 25 other emerging markets worldwide, reflecting its global outreach. Additionally, Zydus Lifesciences has achieved World Health Organization (WHO) prequalification for certain products, enhancing its ability to supply medicines to these regions. The company's focus on affordability and accessibility has bolstered its position in these markets.

3Geographic Strategy

Zydus Lifesciences Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Zydus Lifesciences has a commendable track record with the U.S. Food and Drug Administration (FDA). The company has multiple FDA facility registrations, indicating its compliance with U.S. manufacturing standards. Zydus Lifesciences has received approvals for several Abbreviated New Drug Applications (ANDAs), allowing it to market generic versions of branded drugs in the U.S. market. The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about its manufacturing processes and quality control measures. Zydus Lifesciences' facilities have undergone FDA inspections, reflecting its commitment to maintaining high-quality standards.

2WHO & EU GMP

Zydus Lifesciences has achieved World Health Organization (WHO) prequalification for certain products, demonstrating compliance with international quality standards. The company has also obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements of the European market. These certifications underscore Zydus Lifesciences' dedication to quality and its ability to supply medicines to global markets.

3CDSCO & Indian Regulatory

Zydus Lifesciences Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Zydus Lifesciences operates in a competitive landscape with several key players in the pharmaceutical industry. Top competitors include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Ltd, and Lupin Ltd. In overlapping therapeutic categories, Zydus Lifesciences competes with these companies in areas such as cardiovascular, gastrointestinal, and vitamins & supplements. Market share comparisons indicate that Zydus Lifesciences holds leading positions in certain products, such as Losartan, Carvedilol, and Iron, where it is the market leader. This competitive positioning underscores the company's strength in specific therapeutic segments.

2Key Differentiators

Zydus Lifesciences' key differentiators include its extensive product portfolio, which spans 81 products across 25 therapeutic categories. The company's leadership in specific products, such as Losartan, Carvedilol, and Iron, highlights its competitive advantages. Additionally, Zydus Lifesciences' global manufacturing capabilities, with over 30 manufacturing sites worldwide, enable it to meet diverse market demands. The company's focus on innovation, with a dedicated team of over 1,400 scientists engaged in research and development, supports its ability to introduce differentiated medicines.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Zydus Lifesciences Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Zydus Lifesciences has a strong track record as a pharmaceutical supplier, with a total export value of $346.3 million USD and 9,173 shipments across 81 products in 25 therapeutic categories. The company's top five products—Losartan, Carvedilol, Iron, Mesalamine, and Omeprazole—account for 30% of its portfolio, indicating a focused approach in key therapeutic areas. Zydus Lifesciences' manufacturing facilities are registered with the FDA, and the company holds EU GMP certificates, ensuring compliance with international quality standards. These factors contribute to the company's reliability as a supplier in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications when considering Zydus Lifesciences as a supplier:

FDA Facility Registration: Confirm that the manufacturing facilities are registered with the U.S. Food and Drug Administration. This can be verified through the FDA's Establishment Registration & Device Listing database.

WHO-GMP Certification: Ensure that the products have been prequalified by the World Health Organization's Good Manufacturing Practice standards. Verification can be done by checking the WHO's list of prequalified manufacturers.

Frequently Asked Questions — Zydus Lifesciences Limited

How many pharmaceutical products does Zydus Lifesciences Limited export from India?

Zydus Lifesciences Limited exports 81 pharmaceutical products across 25 therapeutic categories. The top exports are Losartan ($28.1M), Carvedilol ($21.9M), Iron ($21.6M), Mesalamine ($19.3M), Omeprazole ($13.2M). Total export value is $346.3M.

What is Zydus Lifesciences Limited's total pharmaceutical export value?

Zydus Lifesciences Limited's total pharmaceutical export value is $346.3M, based on 9,173 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Zydus Lifesciences Limited the #1 Indian exporter?

Zydus Lifesciences Limited is the #1 Indian exporter in 11 products: Losartan (9.3% market share), Carvedilol (22.3% market share), Iron (4.4% market share), Mesalamine (1.5% market share), Spironolactone (6.6% market share), Chloroquine (7.6% market share), Hydroxychloroquine (9.2% market share), Fluconazole (12.0% market share), Doxycycline (3.3% market share), Leflunomide (25.2% market share).

What therapeutic categories does Zydus Lifesciences Limited cover?

Zydus Lifesciences Limited exports across 25 therapeutic categories. The largest are Cardiovascular (23.2%, 13 products), Gastrointestinal (10.9%, 6 products), Vitamins & Supplements (10.3%, 4 products).

Get Full Zydus Lifesciences Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.